Incyte Corp
NASDAQ:INCY
Incyte Corp
Accounts Receivables
Incyte Corp
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Incyte Corp
NASDAQ:INCY
|
Accounts Receivables
$745.5m
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
32%
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Incyte Corp's Accounts Receivables?
Accounts Receivables
745.5m
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Accounts Receivables amounts to 745.5m USD.
What is Incyte Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
32%
Over the last year, the Accounts Receivables growth was 20%. The average annual Accounts Receivables growth rates for Incyte Corp have been 23% over the past three years , 25% over the past five years , and 32% over the past ten years .